<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131874">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385150</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000702952</org_study_id>
    <secondary_id>ECOG-E1900T8</secondary_id>
    <nct_id>NCT01385150</nct_id>
  </id_info>
  <brief_title>Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Analysis of Serum 2-Hydroxyglutarate (2HG) Levels, IDH Mutations and Clinical Outcome in Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
      doctors identify and lean more about biomarkers related to cancer.

      PURPOSE: This research study is studying biomarkers in blood samples from patients with
      acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if serum 2-hydroxyglutarate (2HG) is only detected in acute myeloid
           leukemia (AML) patients with isocitrate dehydrogenase (IDH) mutations.

      Secondary

        -  To determine if the level of serum 2HG impacts leukemia-free survival (LFS).

        -  To determine if the level of serum 2HG impacts overall survival (OS).

        -  To determine if serum 2HG is undetectable at the time of documented clinical remission
           (CR) in IDH-mutated patients.

      OUTLINE: Archived serum samples are analyzed for 2-hydroxyglutarate expression by
      reverse-phase liquid chromatography coupled to mass spectrometry. Results are then compared
      with presence or absence of an IDH mutation, patients' clinical outcome, as well as age,
      sex, white blood cell count at diagnosis, platelet count, bone marrow blast percentage at
      diagnosis, circulating (serum) percentage at diagnosis, cytogenetic risk group, presence of
      FLT3, NPMN1, and/or TET2 mutations, specific IDH mutation, and randomization treatment group
      allocation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Absence of serum 2HG in all samples without an IDH mutation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between 2HG level and survival outcomes</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liquid chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Morphologically confirmed acute myeloid leukemia (AML)

               -  Newly diagnosed with AML

               -  Serum samples from patients enrolled on the ECOG-1900 clinical trial between
                  2002 and 2008

               -  Patients with or without isocitrate dehydrogenase (IDH) mutations

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Received 2 different doses of standard induction chemotherapy on ECOG-1900
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Courtney DiNardo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>July 7, 2011</lastchanged_date>
  <firstreceived_date>June 28, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Robert L. Comis</name_title>
    <organization>ECOG Group Chair's Office</organization>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
